Oculis Holding
OCS
57 hedge funds and large institutions have $535M invested in Oculis Holding in 2026 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 7 closing their positions.
229% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 7
47% more capital invested
Capital invested by funds: $364M → $535M (+$171M)
39% more funds holding
Funds holding: 41 → 57 (+16)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
0.19% more ownership
Funds ownership: 34.51% → 34.71% (+0.19%)
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $13K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$23.8M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$22.1M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$11.4M |
| 4 |
F
Folketrygdfondet
Oslo Norway,
Norway
|
+$3.62M |
| 5 |
HF
HRT Financial
New York
|
+$2.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
-$16.1M |
| 2 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
-$4.34M |
| 3 |
NICM
Neo Ivy Capital Management
New York
|
-$2.55M |
| 4 |
PBM
Propel Bio Management
Los Angeles,
California
|
-$1.34M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$914K |
OCS Hedge Fund Activity: Q1 2026 in Review
57 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Oculis Holding (OCS) for Q1 2026, worth a combined $535M — up 47% from $364M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new OCS positions and 7 closed out — a net gain of 16 holders — while 11 added to existing stakes and 11 trimmed.
The largest buyer was Millennium Management, adding an estimated $23.8M. The largest seller was Pivotal bioVenture Partners Investment Advisor, cutting an estimated $16.1M.
- 57 institutional investors held Oculis Holding (OCS) as of Q1 2026, up from 41 in Q4 2025.
- Funds reported $535M of Oculis Holding stock for Q1 2026, up 47% quarter-over-quarter.
- 23 funds opened new Oculis Holding positions in Q1 2026 and 7 closed out, a net change of +16 holders.
- The largest Oculis Holding buyer in Q1 2026 was Millennium Management, an estimated $23.8M added.
- The largest Oculis Holding seller in Q1 2026 was Pivotal bioVenture Partners Investment Advisor, an estimated $16.1M sold.
Based on aggregated 13F filings for Q1 2026.